$ABCL AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile • BioPharmCatalyst https://t.co/bXWj9FAkcA
View on X ↗